SRR1797241
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- OXIDATIVE_PHOSPHORYLATION+0.360
- INTERFERON_ALPHA_RESPONSE+0.300
- PROTEIN_SECRETION+0.280
- DNA_REPAIR+0.270
- ADIPOGENESIS+0.200
- HEME_METABOLISM+0.200
- MYC_TARGETS_V1+0.180
- PI3K_AKT_MTOR_SIGNALING+0.150
- MITOTIC_SPINDLE+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- HEDGEHOG_SIGNALING-0.390
- ANGIOGENESIS-0.340
- COAGULATION-0.310
- ALLOGRAFT_REJECTION-0.290
- APICAL_SURFACE-0.290
- KRAS_SIGNALING_DN-0.290
- MYOGENESIS-0.270
- KRAS_SIGNALING_UP-0.260
- TNFA_SIGNALING_VIA_NFKB-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650201 | — | — | 0.858 |
| 2 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.836 |
| 3 | SRR650140 | — | — | 0.820 |
| 4 | SRR975555 | — | — | 0.819 |
| 5 | R28 | — | — | 0.809 |
| 6 | TCGA-75-6207-01A-11R-1755-07 | — | cohortA1 | 0.803 |
| 7 | R386 | — | — | 0.799 |
| 8 | R128 | — | — | 0.795 |
| 9 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.791 |
| 10 | MDT-AP-0447 | Med | Medulloblastoma | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |